ORIC’s lung cancer pill shows promise in some settings but is dropped for HER2 mutations

ORIC Pharmaceuticals’ lung cancer pill showed encouraging efficacy as a first- and second-line treatment in lung cancer patients who have a specific genetic mutation targeted by the drug, part of a series of early trial ...